Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associ…

Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the ...
Healio

Q&A: Deupirfenidone’s advance into phase 3 addresses treatment need in IPF

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There are only three therapies for IPF approved by the ...
ascopubs.org

Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.

Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
The American Journal of Managed Care

The Changing Treatment Landscape of IPF and PPF: Toby Maher, MD, PhD

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and pirfenidone. The FIBRONEER trials support nerandomilast's efficacy in reducing ...
MedPage Today

Novel PDE4 Inhibitor Slows IPF Progression

Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...